Chagas disease in the United Kingdom: A review of cases at the hospital for Tropical Diseases London 1995-2018. The current state of detection of Chagas disease in the UK

dc.contributor.authorGonzález Sanz, Marta
dc.contributor.authorSario, Valentina De
dc.contributor.authorGarcía Mingo, Ana
dc.contributor.authorNolder, Debbie
dc.contributor.authorDawood, Naghum
dc.contributor.authorÁlvarez Martínez, Míriam
dc.contributor.authorDaly, Rosemarie
dc.contributor.authorLowe, Patricia
dc.contributor.authorYacoub, Sophie
dc.contributor.authorMoore, David A. J.
dc.contributor.authorChiodini, Peter L.
dc.date.accessioned2021-02-22T07:30:00Z
dc.date.available2021-02-22T07:30:00Z
dc.date.issued2020-08
dc.date.updated2021-02-19T19:01:46Z
dc.description.abstractBackground: Chagas disease (CD), is a parasitic disease endemic in Latin America. Presentation in non-endemic areas is either in the asymptomatic indeterminate phase or the chronic phase with cardiac and/or gastrointestinal complications. Methods: The Hospital for Tropical Diseases (HTD) based in central London, provides tertiary care for the management of CD. We reviewed all cases managed at this centre between 1995 and 2018. Results: Sixty patients with serologically proven CD were identified. Most were female (70%), with a median age at diagnosis of 41 years. Three quarters of the patients were originally from Bolivia. 62% of all patients were referred to the HTD by their GP. Nearly half of the patients were asymptomatic (47%). Twelve patients had signs of cardiac involvement secondary to CD. Evidence of gastrointestinal damage was established in three patients. Treatment was provided at HTD for 31 patients (47%). Most patients (29) received benznidazole, five of them did not tolerate the course and were switched to nifurtimox. Of the seven patients receiving this second line drug, five completed treatment, whilst two interrupted it due to side effects. Conclusions: Despite the UK health system having all the resources required to diagnose, treat and follow up cases, there is lack of awareness of CD, such that the vast majority of cases remain undiagnosed and therefore do not receive treatment. We propose key interventions to improve the detection and management of this condition in the UK, especially in pregnant women and neonates.
dc.format.extent6 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid32497767
dc.identifier.urihttps://hdl.handle.net/2445/174061
dc.language.isoeng
dc.publisherElsevier Ltd.
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1016/j.tmaid.2020.101760
dc.relation.ispartofTravel Medicine and Infectious Disease, 2020, vol. 36
dc.relation.urihttp://dx.doi.org/10.1016/j.tmaid.2020.101760
dc.rightscc by-nc-nd (c) Elsevier Ltd., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.sourceArticles publicats en revistes (ISGlobal)
dc.subject.classificationMalaltia de Chagas
dc.subject.classificationGran Bretanya
dc.subject.otherChagas' disease
dc.subject.otherGreat Britain
dc.titleChagas disease in the United Kingdom: A review of cases at the hospital for Tropical Diseases London 1995-2018. The current state of detection of Chagas disease in the UK
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
Gonzalez_M_Travel_Med_Infect_Dis_2020.pdf
Mida:
288.56 KB
Format:
Adobe Portable Document Format